Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2013 2
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Characterizing different-flavored e-cigarette solutions from user-reported sensory attributes and appeal.
Anderson MK, Whitted L, Mason TB, Pang RD, Tackett AP, Leventhal AM. Anderson MK, et al. Exp Clin Psychopharmacol. 2023 Feb;31(1):46-56. doi: 10.1037/pha0000563. Epub 2022 Apr 25. Exp Clin Psychopharmacol. 2023. PMID: 35467923 Free PMC article.
Among the 10 flavors, vanilla was rated sweetest (B[difference vs. mean of 9 other flavors] = 14.44, 95% CI [10.84, 18.03]), full-flavored tobacco was most bitter, B = 8.34, 95% CI [4.73, 11.96], subtle tobacco was most harsh, B = 5.69, 95% CI [1.70, 9.68], and pepp …
Among the 10 flavors, vanilla was rated sweetest (B[difference vs. mean of 9 other flavors] = 14.44, 95% CI [10.84, 18.03]), full-flavored t …
Clinically meaningful individual differences in opioid withdrawal expression.
Ware OD, Dunn KE. Ware OD, et al. Exp Clin Psychopharmacol. 2023 Dec;31(6):1005-1009. doi: 10.1037/pha0000654. Epub 2023 May 11. Exp Clin Psychopharmacol. 2023. PMID: 37166910
The sample was primarily men (n = 76, 61.3%) with an average age of 34.7 (SD = 11.6). The typical withdrawal syndrome lasted 6.5 days (SD = 4.9) and was most severe at 5.7 (SD = 4.9) days. ...The two clusters are conceptualized here as HIGH (N = 73; 59%) and LOW (N …
The sample was primarily men (n = 76, 61.3%) with an average age of 34.7 (SD = 11.6). The typical withdrawal syndrome lasted 6.5 days …
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Sanders NC, et al. Exp Clin Psychopharmacol. 2013 Aug;21(4):294-302. doi: 10.1037/a0033724. Epub 2013 Jul 15. Exp Clin Psychopharmacol. 2013. PMID: 23855333 Free PMC article. Clinical Trial.
Twenty-four individuals (13 male; 17 Caucasian, 3 African American, 4 Latino; mean age 29.7 years) participated in the detoxification portion of the study (gabapentin, n = 11; placebo, n = 13). Baseline characteristics did not differ significantly between groups. ...Urine …
Twenty-four individuals (13 male; 17 Caucasian, 3 African American, 4 Latino; mean age 29.7 years) participated in the detoxification portio …
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, Lykouras L. Kalkavoura CS, et al. Exp Clin Psychopharmacol. 2013 Aug;21(4):332-41. doi: 10.1037/a0033448. Epub 2013 Jul 8. Exp Clin Psychopharmacol. 2013. PMID: 23834553
In total 80 patients were enrolled; 33 were receiving risperidone, 17 haloperidol, 11 amisulpride, and 8 risperidone microspheres long acting. Based on PRL levels (< 50, 50-99, or > 100 ng/ml), patients were assigned in 3 cabergoline doses (0.25, 0.5, and 1 mg/day in …
In total 80 patients were enrolled; 33 were receiving risperidone, 17 haloperidol, 11 amisulpride, and 8 risperidone microspheres lon …
Diagnostic compared with abstinence outcomes of day treatment and contingency management among cocaine-dependent homeless persons.
Schumacher JE, Milby JB, Wallace D, Simpson C, Frison S, McNamara C, Usdan S. Schumacher JE, et al. Exp Clin Psychopharmacol. 2003 May;11(2):146-57. doi: 10.1037/1064-1297.11.2.146. Exp Clin Psychopharmacol. 2003. PMID: 12755459 Clinical Trial.
Substance use disorder diagnoses were used as a treatment outcome measure in a randomized comparison of day treatment (DT) and day treatment plus contingency management (DT+) among homeless persons with primarily crack/cocaine disorders. Participants (N = 127, DT+ = 69, DT = 58, …
Substance use disorder diagnoses were used as a treatment outcome measure in a randomized comparison of day treatment (DT) and day treatment …
Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.
Xu Y, Goldenson NI, Prakash S, Augustson EM, Shiffman S. Xu Y, et al. Exp Clin Psychopharmacol. 2024 Feb;32(1):3-15. doi: 10.1037/pha0000698. Epub 2023 Dec 21. Exp Clin Psychopharmacol. 2024. PMID: 38127516 Clinical Trial.
U.S. adults who smoke cigarettes (N = 837; M(age) [SD] = 45.99 years [11.48]; 18.76 cigarettes/day [SD = 7.86]; 50.2% female) from an address-based representative panel were randomized to receive JUUL for 6 months (5.0% nicotine; only Virginia Tobacco [N = 285] or choice o …
U.S. adults who smoke cigarettes (N = 837; M(age) [SD] = 45.99 years [11.48]; 18.76 cigarettes/day [SD = 7.86]; 50.2% female) from an …